This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bushe, C. Articles by Smith, S. M Search for Related Content PubMed Articles by Bushe, C. Articles by Smith, S. M Social Bookmarking                   What's this?

Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics

Eli Lilly and Company Ltd, Basingstoke, UK, beesbeesbees{at}blueyonder.co.uk, bushe_chris{at}lilly.com

David Yeomans

Leeds Mental Health Teaching NHS Trust, Clarence House, 11 Clarence Road, Horsforth, Leeds, UK

Tamsin Floyd

Institute of Psychiatry at Kings College London, PO Box 23, Decrespigny Park, Camberwell, London, UK

Shubulade M Smith

Institute of Psychiatry at Kings College London, PO Box 23, Decrespigny Park, Camberwell, London, UK

Hyperprolactinaemia may be associated with hidden longer-term consequences, such as osteoporosis, bone fractures, pituitary tumours and breast cancer. Prolactin data from clinical trials is not always reported in a categorical manner and does not always allow the risk of hyperprolactinaemia to be evaluated for specific patient cohorts. Patients participating in a physical health management programme in the UK for severe mental illness patients — the Well-being Support Programme — had prolactin measurements made regardless of symptoms. Prolactin data from the complete cohort of 178 patients receiving antipsychotics in Leeds and London are reported. Hyperprolactinaemia was measured in 33.1% but more commonly in females than males (47.3% and 17.6%) and was associated with all antipsychotics except clozapine. The highest prevalence rates were found in amisulpride (n=20) 89%, risperidone long-acting intramuscular injection (LAIM) 67% (n=6) and risperidone (n=30) 55% used as antipsychotic monotherapy. Clinically Significant hyperprolactinaemia (>1000 mIU/L ~47 ng/ml) was measured in 15.8% of patients, predominantly in females. Levels >2000 mIU/L ~95 ng/ml in 6.2% of the complete cohort. Clinicians may wish to add prolactin measurement to the routine laboratory parameters currently measured for some antipsychotics and should be advised of the potential longer-term consequences of hidden hyperprolactinaemia.

Key Words: prolactin • schizophrenia • hyperprolactinaemia • osteoporosis • antipsychotics • breast cancer

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Bushe, M. Shaw, and R. C Peveler A review of the association between antipsychotic use and hyperprolactinaemia J Psychopharmacol, March 1, 2008; 22(2_suppl): 46 - 55. [Abstract] [PDF]

				V. O'Keane Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia J Psychopharmacol, March 1, 2008; 22(2_suppl): 70 - 75. [Abstract] [PDF]